Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3KXMG)

• Drug Name: IZONSTERIDE Drug Info
• Synonyms: Izonsteride < Prop INN; LY-320236; (4aR,10bR)-8-(4-Ethylbenzothiazol-2-ylsulfanyl)-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one

Indication

Disease Entry	ICD 11	Status	REF
Hirsutism	ED72	Phase 1/2	[1]

• Cross-matching ID:
  PubChem CID: 172988
  CAS Number: CAS 176975-26-1
  TTD Drug ID: DM3KXMG

Molecule-Related Drug Atlas

Drug(s) Targeting Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Finasteride	DMWV3TZ	Baldness, male pattern		Approved	[3]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[3]
Polyestradiol Phosphate	DM0PMGJ	Prostate cancer	2C82.0	Approved	[4]
Azelaic Acid	DMHVL0J	Acne vulgaris	ED80	Approved	[5]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[6]
Epristeride	DM35T1O	Hirsutism	ED72	Phase 3	[7]
FK-143	DMEL15U	Prostate disease	GA91	Phase 2	[8]
Turosteride	DMW7PFS	Prostate disease	GA91	Phase 2	[9]
ONO-3805	DM1RKWV	Prostate disease	GA91	Discontinued in Phase 3	[10]
CS-891B	DM17I8O	Alopecia	ED70	Discontinued in Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)	TT2A0DR	S5A1_HUMAN; S5A2_HUMAN; PORED_HUMAN	Modulator	[2]

References

• [1] 5alpha-reductase activity in the prostate. Urology. 2001 Dec;58(6 Suppl 1):17-24; discussion 24.
• [2] Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
• [3] The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
• [8] FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
• [9] Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
• [10] Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7.
• [11] The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5.